Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

  • ID: 4402000
  • Report
  • 188 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Abbott Diagnostics
  • Ceres Nanosciences Inc
  • ImmunID SAS
  • John Hopkins University
  • Orion Genomics LLC
  • Rosetta Genomics Ltd
  • MORE
Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

Summary

The Medical Devices sector report, “Melanoma Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Melanoma Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Melanoma Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Melanoma Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Melanoma Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry
Reasons to buy
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Melanoma Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Diagnostics
  • Ceres Nanosciences Inc
  • ImmunID SAS
  • John Hopkins University
  • Orion Genomics LLC
  • Rosetta Genomics Ltd
  • MORE
1 Table of Contents
2 Introduction
2.1 Melanoma Diagnostic Tests Overview
3 Products under Development
3.1 Melanoma Diagnostic Tests - Pipeline Products by Stage of Development
3.2 Melanoma Diagnostic Tests - Pipeline Products by Territory
3.3 Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path
3.4 Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date
3.5 Melanoma Diagnostic Tests - Ongoing Clinical Trials
4 Melanoma Diagnostic Tests - Pipeline Products under Development by Companies
4.1 Melanoma Diagnostic Tests Companies - Pipeline Products by Stage of Development
4.2 Melanoma Diagnostic Tests - Pipeline Products by Stage of Development
5 Melanoma Diagnostic Tests Companies and Product Overview
5.1 Abbott Diagnostics Company Overview
5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
5.2 Adaptive Biotechnologies Corp Company Overview
5.2.1 Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview
5.3 Agilent Technologies Inc Company Overview
5.3.1 Agilent Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.4 BioMark Diagnostics Inc. Company Overview
5.4.1 BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.5 BioMarker Strategies LLC Company Overview
5.5.1 BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview
5.6 Biosceptre International Ltd Company Overview
5.6.1 Biosceptre International Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.7 Ceres Nanosciences Inc Company Overview
5.7.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.8 Dana-Farber Cancer Institute Inc Company Overview
5.8.1 Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
5.9 Digna Biotech SL Company Overview
5.9.1 Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview
5.10 Exosomics Siena SpA Company Overview
5.10.1 Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview
5.11 Genomic Health Inc Company Overview
5.11.1 Genomic Health Inc Pipeline Products & Ongoing Clinical Trials Overview
5.12 Hospital Universitario Cruces Company Overview
5.12.1 Hospital Universitario Cruces Pipeline Products & Ongoing Clinical Trials Overview
5.13 Hummingbird Diagnostics GmbH Company Overview
5.13.1 Hummingbird Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.14 ImmunID SAS Company Overview
5.14.1 ImmunID SAS Pipeline Products & Ongoing Clinical Trials Overview
5.15 Institut Pasteur Company Overview
5.15.1 Institut Pasteur Pipeline Products & Ongoing Clinical Trials Overview
5.16 InterGenetics Inc Company Overview
5.16.1 InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.17 IV Diagnostics Inc Company Overview
5.17.1 IV Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
5.18 John Hopkins University Company Overview
5.18.1 John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
5.19 Louisville Bioscience, Inc. Company Overview
5.19.1 Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.20 MDNA Life Sciences Inc Company Overview
5.20.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
5.21 Melanovus Oncology Inc Company Overview
5.21.1 Melanovus Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview
5.22 Memorial Sloan Kettering Cancer Center Company Overview
5.22.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
5.23 MyCardio LLC Company Overview
5.23.1 MyCardio LLC Pipeline Products & Ongoing Clinical Trials Overview
5.24 Orion Genomics LLC Company Overview
5.24.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
5.25 Oryzon Genomics SA Company Overview
5.25.1 Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview
5.26 Pacific Edge Ltd Company Overview
5.26.1 Pacific Edge Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.27 Protea Biosciences Group Inc Company Overview
5.27.1 Protea Biosciences Group Inc Pipeline Products & Ongoing Clinical Trials Overview
5.28 Qiagen NV Company Overview
5.28.1 Qiagen NV Pipeline Products & Ongoing Clinical Trials Overview
5.29 Roche Diagnostics International Ltd Company Overview
5.29.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.30 Rosetta Genomics Ltd Company Overview
5.30.1 Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.31 Sividon Diagnostics GmbH Company Overview
5.31.1 Sividon Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
5.32 SomaLogic Inc Company Overview
5.32.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview
5.33 Treos Bio Inc Company Overview
5.33.1 Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
5.34 University of California San Francisco Company Overview
5.34.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview
5.35 University of Louisville Company Overview
5.35.1 University of Louisville Pipeline Products & Ongoing Clinical Trials Overview
5.36 University of Maryland Baltimore Company Overview
5.36.1 University of Maryland Baltimore Pipeline Products & Ongoing Clinical Trials Overview
5.37 Vanderbilt University Company Overview
5.37.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview
5.38 Zymera, Inc Company Overview
5.38.1 Zymera, Inc Pipeline Products & Ongoing Clinical Trials Overview
6 Melanoma Diagnostic Tests - Recent Developments
6.1 Sep 05, 2017: Rosetta Genomics to Reduce Operating and Other Expenses
6.2 Aug 31, 2017: BioMarker Strategies Announces Two New Patents Granted in Japan, For the Company’s Core Diagnostics Technology PathMAP
6.3 Aug 30, 2017: bioMerieux - First-Half 2017 Results
6.4 Aug 30, 2017: GSK responds to UK Life Sciences Industrial Strategy
6.5 Aug 22, 2017: Protea Expands Clinical Study for New Melanoma Test
6.6 Aug 15, 2017: Agilent Technologies Reports Third-Quarter Fiscal Year 2017 Financial Results
6.7 Aug 08, 2017: HTG Molecular Diagnostics Reports Second Quarter 2017 Results
6.8 Aug 01, 2017: Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress
6.9 Jul 31, 2017: AtCor Signs New Agreement Major entry point into New York health systems market
6.10 Jul 28, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017
6.11 Jul 27, 2017: Adaptive Biotechnologies Expands Leadership to Bolster Integration of Immune Profiling into Clinical Care Setting
6.12 Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017
6.13 Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group
6.14 Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK
6.15 Jul 25, 2017: Quest Diagnostics Reports Second Quarter 2017 Financial Results, Raises 2017 Financial Outlook
6.16 Jul 21, 2017: GSK announces Board and Committee changes
6.17 Jul 20, 2017: bioMerieux - Second-Quarter 2017 Business Review
6.18 Jul 20, 2017: Professor John Spencer’s Lab to Carry Out Vital Skin Cancer Research Thanks to New Grant
6.19 Jul 18, 2017: Hans E. Bishop to Join Agilent's Board of Directors
6.20 Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China
6.21 Jun 19, 2017: GSK confirms start date for Luke Miels
6.22 Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation
6.23 Jun 01, 2017: MolecularMD achieves status as an ArcherDX Certified Service Provider and expands offering of novel NGS chemistries
6.24 May 22, 2017: Agilent Technologies Reports Second-Quarter Fiscal Year 2017 Financial Results
6.25 May 16, 2017: Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department
6.26 May 15, 2017: HTG Molecular Diagnostics Reports First Quarter 2017 Results
6.27 May 09, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2017
6.28 May 09, 2017: Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress
6.29 May 04, 2017: Agilent Technologies Receives Multiple Awards at Scientific Conference in China
6.30 May 02, 2017: QIAGEN reports results for first quarter 2017
6.31 May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results
6.32 May 01, 2017: Rosetta Genomics Expands Patent Portfolio in Europe and Japan
6.33 Apr 26, 2017: GSK delivers another quarter of continued progress
6.34 Apr 20, 2017: Quest Diagnostics Reports First Quarter 2017 Financial Results, Raises 2017 Financial Outlook
6.35 Apr 20, 2017: bioMerieux - First-Quarter 2017 Business Review
6.36 Apr 18, 2017: Protea Announces 2016 Year End Results
6.37 Apr 05, 2017: SomaLogic announces the appointment of long-time Board member as Chief Executive Officer
6.38 Apr 04, 2017: GSK responds to Cyclone Debbie
6.39 Mar 30, 2017: Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results
6.40 Mar 23, 2017: HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2016 Results
6.41 Mar 20, 2017: Agilent Technologies Hires Samraat Sam Raha to Head Strategy and Corporate Development
6.42 Mar 15, 2017: Agilent Technologies Board of Directors Elects Koh Boon Hwee as New Chairman
6.43 Mar 14, 2017: Agilent Technologies Receives 2017 Scientists’ Choice Award for Best Webinar Series
6.44 Mar 07, 2017: HTG Molecular Diagnostics Appoints New Chair of the Board of Directors
6.45 Mar 01, 2017: bioMerieux - 2016 Financial Results
6.46 Feb 24, 2017: ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016
6.47 Feb 21, 2017: Agilent Technologies Receives Dow's Western Canada Science and Technical Excellence Conference Awards (WesTEC) for Technical Excellence and Innovation
6.48 Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms
6.49 Feb 14, 2017: Agilent Technologies Reports First-Quarter 2017 Results
6.50 Feb 14, 2017: Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook
6.51 Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016
6.52 Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results
6.53 Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016
6.54 Jan 26, 2017: Quest Diagnostics Reports Fourth Quarter And Full Year 2016 Financial Results; Provides Guidance For Full Year 2017
6.55 Jan 26, 2017: Quest Diagnostics Partners With Montefiore Health System to Deliver High-Value, Innovative Laboratory Services
6.56 Jan 19, 2017: bioMerieux - Fourth-Quarter 2016 Business Review
6.57 Jan 19, 2017: Abbas Hussain to leave GSK
6.58 Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK
6.59 Dec 21, 2016: Agilent Technologies Receives Top Innovation Award from The Analytical Scientist
6.60 Dec 19, 2016: GSK announces Board changes
6.61 Dec 15, 2016: Quest Diagnostics Board of Directors Elects Stephen H. Rusckowski Chairman of the Board
6.62 Nov 24, 2016: Pacific Edge Interim Results to 30 September 2016
6.63 Nov 22, 2016: Protea Announces Third Quarter 2016 Results
6.64 Nov 15, 2016: Agilent Technologies Reports Fourth-Quarter 2016 Results
6.65 Nov 14, 2016: HTG Molecular Diagnostics Reports Third Quarter 2016 Results
6.66 Nov 11, 2016: Quest Diagnostics Raises Revenue Growth Outlook, Increases Dividend at 2016 Investor Day
6.67 Nov 10, 2016: Protea Appoints David Halverson As President
6.68 Nov 07, 2016: Pierre Boulud appointed Corporate Vice Presidentof the Asia Pacific region at bioMerieux
6.69 Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016
6.70 Nov 02, 2016: QIAGEN launches restructuring initiatives, revises outlook for 2016 earnings and provides initial net sales and adjusted earnings guidance for 2017
6.71 Nov 01, 2016: Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results
6.72 Nov 01, 2016: Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
6.73 Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016
6.74 Oct 24, 2016: ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016
6.75 Oct 20, 2016: bioMerieux-Business Review for the nine months ended September 30, 2016
6.76 Oct 20, 2016: Quest Diagnostics Reports Third Quarter 2016 Financial Results
6.77 Oct 20, 2016: Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer
6.78 Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare
6.79 Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy
6.80 Sep 26, 2016: Rosetta Genomics Reports 2016 Second Quarter Financial Results
7 Appendix
7.1 Methodology
7.2 About
7.3 Contact
7.4 Disclaimer

List of Tables
Table 1: Melanoma Diagnostic Tests - Pipeline Products by Stage of Development
Table 2: Melanoma Diagnostic Tests - Pipeline Products by Territory
Table 3: Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path
Table 4: Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date
Table 5: Melanoma Diagnostic Tests - Ongoing Clinical Trials
Table 6: Melanoma Diagnostic Tests Companies - Pipeline Products by Stage of Development
Table 7: Melanoma Diagnostic Tests - Pipeline Products by Stage of Development
Table 8: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
Table 9: MAGE-A3 Companion Diagnostic Assay - Melanoma - Product Status
Table 10: MAGE-A3 Companion Diagnostic Assay - Melanoma - Product Description
Table 11: Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Companion Diagnostic Test - Melanoma Cancer - Product Status
Table 13: Companion Diagnostic Test - Melanoma Cancer - Product Description
Table 14: Agilent Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 15: MK-3475 Companion Diagnostic Test - Product Status
Table 16: MK-3475 Companion Diagnostic Test - Product Description
Table 17: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 18: Metabolomics-Based Diagnostic Assay - Melanoma - Product Status
Table 19: Metabolomics-Based Diagnostic Assay - Melanoma - Product Description
Table 20: BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 21: Ex Vivo Biomarker Test - Melanoma - Product Status
Table 22: Ex Vivo Biomarker Test - Melanoma - Product Description
Table 23: PathMAP - Product Status
Table 24: PathMAP - Product Description
Table 25: Biosceptre International Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Skin Cancer IHC Diagnostic Test - Product Status
Table 27: Skin Cancer IHC Diagnostic Test - Product Description
Table 28: Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Melanoma Skin Patch Sweat Test - Product Status
Table 30: Melanoma Skin Patch Sweat Test - Product Description
Table 31: Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Status
Table 33: Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Description
Table 34: Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview
Table 35: Melanoma Test - Product Status
Table 36: Melanoma Test - Product Description
Table 37: Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview
Table 38: ExoTEST Melanoma - Product Status
Table 39: ExoTEST Melanoma - Product Description
Table 40: Genomic Health Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Prognostic Test - Melanoma - Product Status
Table 42: Prognostic Test - Melanoma - Product Description
Table 43: Hospital Universitario Cruces Pipeline Products & Ongoing Clinical Trials Overview
Table 44: Diagnostic Assay - Melanoma - Product Status
Table 45: Diagnostic Assay - Melanoma - Product Description
Table 46: Hummingbird Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 47: Diagnostic Test - Melanoma - Product Status
Table 48: Diagnostic Test - Melanoma - Product Description
Table 49: ImmunID SAS Pipeline Products & Ongoing Clinical Trials Overview
Table 50: ImmunTraCkeR - Metastatic Melanoma - Product Status
Table 51: ImmunTraCkeR - Metastatic Melanoma - Product Description
Table 52: ImmunID SAS - Ongoing Clinical Trials Overview
Table 53: ImmunTraCkeR - Metastatic Melanoma - Multicenter Clinical Study to Assess the Use of Immune Competence Profiles evaluated by ImmunTracker in Metastatic Melanoma Subjects Treated with an Immune Checkpoint Inhibitor
Table 54: ImmunTraCkeR - Metastatic Melanoma - Validation of ImmunTraCkeR in Metastatic Melanoma Patients - A Medico-economic Clinical Study
Table 55: Institut Pasteur Pipeline Products & Ongoing Clinical Trials Overview
Table 56: Diagnostic Test - Melanoma - Product Status
Table 57: Diagnostic Test - Melanoma - Product Description
Table 58: InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 59: OncoVue Skin - Product Status
Table 60: OncoVue Skin - Product Description
Table 61: IV Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 62: IVDiagnostics Diagnostic Test - Melanoma - Product Status
Table 63: IVDiagnostics Diagnostic Test - Melanoma - Product Description
Table 64: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
Table 65: Biomarker Based Diagnostic Assay - Melanoma - Product Status
Table 66: Biomarker Based Diagnostic Assay - Melanoma - Product Description
Table 67: Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 68: Melanoma Remission pT Test - Product Status
Table 69: Melanoma Remission pT Test - Product Description
Table 70: MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 71: Diagnostic Test - Melanoma - Product Status
Table 72: Diagnostic Test - Melanoma - Product Description
Table 73: Melanovus Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 74: Companion Diagnostic Test - Melanoma - Product Status
Table 75: Companion Diagnostic Test - Melanoma - Product Description
Table 76: Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
Table 77: Melanoma Biomarker - Resistance to RAF Inhibitors - Product Status
Table 78: Melanoma Biomarker - Resistance to RAF Inhibitors - Product Description
Table 79: MyCardio LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 80: Diagnostic Assay - Melanoma - Product Status
Table 81: Diagnostic Assay - Melanoma - Product Description
Table 82: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 83: Diagnostic Assay - Melanoma - Product Status
Table 84: Diagnostic Assay - Melanoma - Product Description
Table 85: Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview
Table 86: Diagnostic Assay - Melanoma Cancer - Product Status
Table 87: Diagnostic Assay - Melanoma Cancer - Product Description
Table 88: Prognostic Assay - Melanoma Cancer - Product Status
Table 89: Prognostic Assay - Melanoma Cancer - Product Description
Table 90: Pacific Edge Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 91: Prognostic Assay - Melanoma - Product Status
Table 92: Prognostic Assay - Melanoma - Product Description
Table 93: Protea Biosciences Group Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 94: Mass Spectrometry Imaging Based Test - Malignant Melanoma - Product Status
Table 95: Mass Spectrometry Imaging Based Test - Malignant Melanoma - Product Description
Table 96: Protea Biosciences Group Inc - Ongoing Clinical Trials Overview
Table 97: Mass Spectrometry Imaging Based Test - Malignant Melanoma - Clinical Research Study for New Molecular Imaging Test for the Differential Diagnosis of Malignant Melanoma
Table 98: Qiagen NV Pipeline Products & Ongoing Clinical Trials Overview
Table 99: Companion Diagnostic Test - Binimetinib - Product Status
Table 100: Companion Diagnostic Test - Binimetinib - Product Description
Table 101: QIAsymphony - NRAS Assay - Product Status
Table 102: QIAsymphony - NRAS Assay - Product Description
Table 103: Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 104: Cobimetinib Companion Diagnostic Assay - Product Status
Table 105: Cobimetinib Companion Diagnostic Assay - Product Description
Table 106: Companion Diagnostic Test - MEK 0973 - Product Status
Table 107: Companion Diagnostic Test - MEK 0973 - Product Description
Table 108: ETBR ADC Companion Diagnostic Test - Product Status
Table 109: ETBR ADC Companion Diagnostic Test - Product Description
Table 110: PDL1+Zelboraf Companion Diagnostic Test - Product Status
Table 111: PDL1+Zelboraf Companion Diagnostic Test - Product Description
Table 112: Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Status
Table 113: Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Description
Table 114: Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 115: microRNA-Based Diagnostic Test - Melanoma - Product Status
Table 116: microRNA-Based Diagnostic Test - Melanoma - Product Description
Table 117: Sividon Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 118: Diagnostic Assay - Melanoma - Product Status
Table 119: Diagnostic Assay - Melanoma - Product Description
Table 120: SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 121: SOMAscan Assay - Melanoma - Product Status
Table 122: SOMAscan Assay - Melanoma - Product Description
Table 123: Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 124: PolyPEPI 613 CDx - Product Status
Table 125: PolyPEPI 613 CDx - Product Description
Table 126: University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview
Table 127: Diagnostic Assay - Uveal Melanoma - Product Status
Table 128: Diagnostic Assay - Uveal Melanoma - Product Description
Table 129: University of Louisville Pipeline Products & Ongoing Clinical Trials Overview
Table 130: Melanoma Sentinel Lymph Node Biomarker Test - Product Status
Table 131: Melanoma Sentinel Lymph Node Biomarker Test - Product Description
Table 132: University of Maryland Baltimore Pipeline Products & Ongoing Clinical Trials Overview
Table 133: Prognostic Biomarker Test - Melanoma - Product Status
Table 134: Prognostic Biomarker Test - Melanoma - Product Description
Table 135: Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview
Table 136: Companion Diagnostic Assay - Melanoma - Product Status
Table 137: Companion Diagnostic Assay - Melanoma - Product Description
Table 138: Zymera, Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 139: Prognostic Assay - Melanoma - Product Status
Table 140: Prognostic Assay - Melanoma - Product Description
Table 141: Glossary

List of Figures
Figure 1: Melanoma Diagnostic Tests - Pipeline Products by Stage of Development
Figure 2: Melanoma Diagnostic Tests - Pipeline Products by Territory
Figure 3: Melanoma Diagnostic Tests - Pipeline Products by Regulatory Path
Figure 4: Melanoma Diagnostic Tests - Pipeline Products by Estimated Approval Date
Figure 5: Melanoma Diagnostic Tests - Ongoing Clinical Trials
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Diagnostics
  • Adaptive Biotechnologies Corp
  • Agilent Technologies Inc
  • BioMark Diagnostics Inc.
  • BioMarker Strategies LLC
  • Biosceptre International Ltd
  • Ceres Nanosciences Inc
  • Dana-Farber Cancer Institute Inc
  • Digna Biotech SL
  • Exosomics Siena SpA
  • Genomic Health Inc
  • Hospital Universitario Cruces
  • Hummingbird Diagnostics GmbH
  • ImmunID SAS
  • Institut Pasteur
  • InterGenetics Inc
  • IV Diagnostics Inc
  • John Hopkins University
  • Louisville Bioscience, Inc.
  • MDNA Life Sciences Inc
  • Melanovus Oncology Inc
  • Memorial Sloan Kettering Cancer Center
  • MyCardio LLC
  • Orion Genomics LLC
  • Oryzon Genomics SA
  • Pacific Edge Ltd
  • Protea Biosciences Group Inc
  • Qiagen NV
  • Roche Diagnostics International Ltd
  • Rosetta Genomics Ltd
  • Sividon Diagnostics GmbH
  • SomaLogic Inc
  • Treos Bio Inc
  • University of California San Francisco
  • University of Louisville
  • University of Maryland Baltimore
  • Vanderbilt University
  • Zymera, Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll